Daraxonrasib FDA Approval Makes RAS a Pancreatic Cancer Drug Target

A long-standing barrier in oncology gives way

For about four decades, cancer researchers treated RAS as the target they knew mattered most and could least reach with a drug. Since August 26, 2026, that is no longer true for pancreatic cancer. On that date, the US Food and Drug Administration approved daraxonrasib, sold by Revolution Medicines as Rasonque. It is an inhibitor of the RAS GTPase family, cleared for adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.12 The drug is a once-daily 300 mg tablet, and the company said physicians could begin prescribing it right away.16

Most of the coverage reaches the same conclusion, and I agree with it: this is the biggest therapeutic advance in pancreatic cancer in a generation. The reasons for that conclusion, and the open questions behind it, deserve a closer look.

What the trial showed

The approval rests on RASolute 302, a randomized, open-label, multicenter phase 3 trial. It enrolled 500 adults with metastatic pancreatic ductal adenocarcinoma whose disease had progressed on a fluoropyrimidine- or gemcitabine-based regimen.8 The investigator who led it was Brian Wolpin of Dana-Farber Cancer Institute. He presented the results at the 2026 ASCO Annual Meeting, they were published in the New England Journal of Medicine, and the patients came from North America, Europe and Asia.11

The main result is simple. Median overall survival was 13.2 months on daraxonrasib and 6.7 months on chemotherapy, with a hazard ratio of 0.40, which works out to roughly a 60% lower risk of death.11 Response rates followed the same pattern: 31.6% of patients in the overall population had confirmed responses on daraxonrasib, compared with 11.2% on chemotherapy.18 The drug also delayed worsening of cancer-related pain (9.2 versus 3.8 months) and of global health status and quality of life (5.7 versus 2.6 months).2

The published figures differ slightly from outlet to outlet. The differences come from which patient group each outlet reported, not from any dispute about the data. Dana-Farber gave median progression-free survival as 7.2 versus 3.6 months for the full study population.11 Trade outlets reported 7.3 versus 3.5 months, and chemotherapy-arm survival of 6.6 rather than 6.7 months, for the subgroup with RAS G12 mutations.2 Both sets of numbers are correct. The point that matters is that the benefit held up in both groups. The FDA itself said the trial showed statistically significant gains in overall survival, progression-free survival and response rate in the RAS G12 group and in the overall population.12

The side-effect profile is not trivial, but no outlet called it disqualifying. Reported adverse events include rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite and hemorrhage.8 Dana-Farber said the phase 3 trial raised no new safety signals compared with the earlier phase 1/2 study.11 Because patients take the drug at home, nursing publications stress that managing adherence and side effects now shifts to outpatient monitoring.1

How the drug works

Daraxonrasib is described as a noncovalent tri-complex inhibitor. It attaches to an intracellular protein, cyclophilin A, and that pairing then binds active, GTP-bound RAS. This works across G12, G13 and Q61 mutations and on non-mutated RAS as well.18 Dana-Farber calls it a molecular glue that blocks RAS signaling together with cyclophilin A.11

The breadth of that mechanism explains why the approval matters as much as it does. More than 90% of pancreatic cancers carry cancer-driving mutations in KRAS, a member of the RAS family.13 Those mutations come in several forms, including G12D, G12V and G12R. A drug aimed at only one of them would leave many patients without an option.9 Daraxonrasib hits several mutant forms of RAS at once, which is why the label can cover so much of the disease.

A label wider than the trial population

The label is the part of this story that has received too little attention. Revolution Medicines says the approval applies to metastatic pancreatic adenocarcinoma whether or not a RAS mutation has been identified, and that no companion diagnostic test is required.16 For a targeted therapy, that is unusual. The company's chief executive, Mark Goldsmith, described it as a label that "supports real-world clinical decision-making."8

The guidance in Europe is narrower. In August 2026, the European Society for Medical Oncology issued a guideline update recommending daraxonrasib monotherapy after progression on chemotherapy specifically for patients with RAS G12-mutated metastatic disease and an ECOG performance status of 0 or 1.18 The European Medicines Agency's review is still in progress; the phased assessment began in July.2

The trial data partly explain the gap. About 91.8% of enrolled patients had RAS G12 mutations.9 The evidence for patients without a detected mutation therefore comes from a fairly small group. My reading is that the FDA made a defensible practical choice, because nearly every pancreatic tumor is RAS-driven and requiring a test would only slow access. Even so, oncologists should expect the benefit in patients without a detected mutation to be examined closely as real-world data accumulate.

An unusually fast review

The regulatory timeline is a story of its own. The agency approved the drug about 6.5 months before its user-fee goal date. It used the Real-Time Oncology Review pilot, which lets sponsors submit data before the full application is filed, along with the voluntary Assessment Aid.12 The application was also reviewed under the Commissioner's National Priority Voucher pilot program. The FDA accepted it for review on July 22, 2026, with an expected review time of one to two months.2 By late August it was approved.

The drug also held Breakthrough Therapy, Orphan Drug and Priority Review designations.1 Patients could get it through an expanded access program authorized in May 2026, before approval.2 Mass General Brigham says its oncologists had been prescribing the drug since July 2026 as one of the few centers offering it before approval.6

Agency officials clearly want this case seen as a showcase. Acting Commissioner Kyle Diamantas praised the "fast, thorough review," and Oncology Center of Excellence director Angelo de Claro presented the early decision as evidence of the FDA's commitment to speeding up cancer approvals.2 In this instance the speed seems well justified. A doubling of overall survival in a randomized phase 3 trial is the strongest kind of evidence a regulator can get, and the voucher program could hardly have asked for a better test case. Pharma trade coverage noted that observers had picked Revolution as a strong candidate for a voucher when the first awards were announced.8 Whether the voucher pathway works as well for less clear-cut applications is something this approval cannot show.

Where the coverage overstates

Some coverage stretches the claims. One outlet called daraxonrasib the first oral targeted pill ever cleared for pancreatic cancer.5 Another called it the first targeted therapy approved for the disease.10 The FDA's own wording is narrower: "first-in-class."9 The Pancreatic Cancer Action Network chose its words carefully as well, calling it the first RAS-targeting therapy that is broadly effective in this disease.14 That narrower claim is the accurate one, and it is impressive enough without inflation.

Accounts of who deserves credit also differ. A Boston public-radio piece said the drug was developed by Dana-Farber and that Wolpin's lab work led to it.7 Revolution Medicines was founded in 2014 on the bet that RAS could be drugged, and Rasonque is its first commercial product.8 Dana-Farber describes its own role as helping to lead the preclinical and clinical research.13 The fair summary is that a company built the molecule and an academic center ran the pivotal trial. Both should be credited, and neither alone.

Why it matters, and what remains

The clinical setting explains why the reaction has been so strong. Pancreatic cancer's five-year survival rate is just 13%.14 Adenocarcinoma makes up as much as 95% of the roughly 67,000 pancreatic cancer cases diagnosed in the US each year.5 Most patients are diagnosed after the disease has already spread.5 Until now, patients who progressed on first-line treatment were mostly offered more intravenous cytotoxic chemotherapy.16 PanCAN now calls daraxonrasib the new standard of care for previously treated metastatic disease.14

The outlook for patients is still sobering. A median survival of 13.2 months is twice the old figure, but in absolute terms it is only about six extra months for a typical patient in this setting. Calling it a cure would be wrong. Even supportive explainers note that RAS inhibition will not work for every patient and that the disease is far from fully controllable.9

What comes next depends on moving the drug into earlier stages of the disease. The phase 3 RASolute 303 trial is testing daraxonrasib in the first-line setting, both alone and combined with gemcitabine plus nab-paclitaxel. RASolute 304 is testing it after surgery in patients with resected disease.2 The company is also running a registrational program in RAS-mutant non-small cell lung cancer, where the drug already has Breakthrough Therapy designation.16 Researchers also point out that liquid-biopsy tests could identify more patients who are eligible for RAS-targeted drugs.4

The second-line approval proves that RAS can be drugged. The first-line and post-surgery trials will show how far that can change outcomes. If daraxonrasib produces benefits of similar size earlier in the disease, when patients are healthier, the claims of a turning point will be fully justified. Until those results arrive, the proof of concept is established and the larger effect on survival is still to be shown.